AUSTIN, Texas–(BUSINESS WIRE)–Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its Signatera molecular residual disease (MRD) test has been named to TIME’s Best Inventions of 2026 list, featuring extraordinary innovations that are changing lives.TIME’s Best Inventions list, published annually, highlights the technologies…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
